RECRUITING

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Talk to us

Conditions

Hiv

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with vs without HIV.

Official Title

HOPE in Action Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes

Quick Facts

Study Start:2024-05-22
Study Completion:2029-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06263426

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant meets local criteria for kidney transplant.
  2. * Participant is able to understand and provide informed consent.
  3. * Participant has documented HIV infection by any licensed assay or documented history of detectable HIV-1 RNA.
  4. * Participant is ≥ 18 years old.
  5. * Cluster of differentiation 4 (CD4+) T-cell count: ≥ 200/μL within 16 weeks of transplant.
  6. * HIV-1 RNA \< 50 copies/mL. Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \> 200 copies/mL.
  7. * Participant is not suffering from significant wasting (e.g. body mass index \<21) thought to be related to HIV disease.
  8. * Participant meets with an independent advocate.
  1. * Participant has prior progressive multifocal leukoencephalopathy (PML), cryptosporidiosis of \> 1 month, or primary central nervous system (CNS) lymphoma.
  2. * Participant is pregnant or breastfeeding.
  3. * Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Contacts and Locations

Study Contact

Christine Durand, MD
CONTACT
410-614-6702
cdurand2@jhmi.edu

Principal Investigator

Christine Durand, MD
PRINCIPAL_INVESTIGATOR
Johns Hopkins University

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35294
United States
University of California, Los Angeles
Los Angeles, California, 90095
United States
University of California, San Diego
San Diego, California, 92037
United States
University of California, San Francisco
San Francisco, California, 94143
United States
Rush University Medical Center
Chicago, Illinois, 60612
United States
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
United States
Johns Hopkins University
Baltimore, Maryland, 21205
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
New York University
New York, New York, 10016
United States
Icahn School of Medicine at Mt. Sinai
New York, New York, 10029
United States
Columbia University
New York, New York, 10032
United States
Weill Cornell Medical Center
New York, New York, 10065
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
United States

Collaborators and Investigators

Sponsor: Johns Hopkins University

  • Christine Durand, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-22
Study Completion Date2029-09

Study Record Updates

Study Start Date2024-05-22
Study Completion Date2029-09

Terms related to this study

Additional Relevant MeSH Terms

  • Hiv